In the pharmaceutical industry the increased efficiency brought about by new fast chromatography methods needs to be matched by commensurate mass spec capabilities. maXis UHR-TOF is the instrument of choice to keep up with fastest chromatography.
Ray Sanchez, Penggao Duan and Darwin Asa, Bruker Daltonics, Billerica, Massachusetts, USA.
In the pharmaceutical industry the increased efficiency brought about by new fast chromatography methods needs to be matched by commensurate mass spec capabilities. maXis UHR-TOF is the instrument of choice to keep up with fastest chromatography.
Figure 1
Many high performance accurate mass and orbital trapping MS systems are unable to provide sufficient high resolution data at fast chromatography speeds. Fast separation technology can significantly reduce the time required to analyse a given sample. Chromatography methods can be reduced sometimes by an order of magnitude. These short run times produce chromatograms with peak widths of less than a few seconds wide. The new maXis system is the only high performance MS system capable of operating with those fast run times without sacrificing resolution or sensitivity. Here we demonstrate the typical results that can be achieved by the combination of fast chromatography with the maXis to analyse a complex pharmaceutical sample.
Figure 2
UHPLC system:
Mobile phase:
Gradient:
Flow rate: 0.6 mL/min
Injection volume: 2 µL
In this study, the maXis was challenged to identify a series of unknown drug compounds that had been separated by UHPLC. Using a typical reverse phase C18 gradient separation method, 7 of the 10 compounds were base line separated by the UHPLC in 85 seconds at 10 Hz sampling rate. The maXis was then able to discern the presence of 10 compounds in the sample, despite the lack of chromatographic separation of three of the compounds, even at levels as low as 10 pg on column. Furthermore, the excellent mass accuracy (<1 ppm) and resolution (avg ~50 K) of the results generated by the maXis, when used in conjunction with the SmartFormula 3D software, were able to use the data to correctly identify all 10 compounds and unequivically determine their molecular formula. This is exceptional performance from a Q-TOF, especially with a UHPLC speed separation.
MS system: Bruker Daltonics maXis
Spectral acquisition 10 full spectra per second
Dry heater 180 °C
Nebulizer 2 Bar
Capillary 4500 V
Dry gas 6 L/min
ESI positive polarity
Range 100–800 m/z
Calibrant Lithium formate (16 mM)
LockMass calibration methylstearate
Technology
Bruker Daltonics has developed a new state of the art mass spectrometer, the maXis, capable of keeping pace with the current demands of high-throughput analysis without sacrificing accuracy, sensitivity or resolution. In this study the maXis was capable of delivering:
For research use only. Not for use in diagnostic procedures.
Bruker Daltonik GmbH
Fahrenheitstr. 4, 28359 Bremen, Germany
tel. +49 421 2205 0 fax +49 421 2205 104
E-mail: sales@bdal.de
Website: www.bdal.com
Using LC-MS/MS Analysis for PFAS Detection in Biological Samples and Serum
November 1st 2024Per- and polyfluoroalkyl substances (PFAS) are exceptionally versatile chemicals and have seemingly endless applications. Due to their persistent nature; prevalence in blood, food and environment; and emerging toxicity, there is a significant concern for their presence in the human body. Analysis is especially complicated due to background contamination in laboratory supplies and system. This paper will discuss sample preparation and LC-MS/MS analysis of an expanded panel of PFAS compounds in serum.
Robust Oligonucleotide Molecular Weight Confirmation via LC/MS
October 31st 2024Oligonucleotides—therapeutic agents for difficult-to-treat diseases—rely on precise molecular weight confirmation to ensure quality during development. Experts from Agilent Technologies explore the challenges of liquid chromatography-mass spectrometry (LC/MS) analysis in oligonucleotide synthesis, as well as strategies for accurate deconvolution, method development, and optimal equipment selection.